The Governing Council of the Community of Madrid has greenlit the acquisition of 1,660,000 doses of anti-flu vaccines for the 2026/27 season, with a total investment of 18.5 million euros. The decision, announced by the regional Executive, aims to enhance public health protection against seasonal influenza.

The vaccination campaign, set to commence next autumn, has calculated the number of doses based on the coverage achieved in the previous season and the number of citizens in priority population groups. Of the vaccines procured, 1,117,000 units will be adjuvanted vaccines, particularly recommended for individuals aged 60 and over and residents in care homes. Additionally, 540,000 doses will be allocated to people between five and 59 years old with at-risk conditions and to infants between six and 24 months old.

A further 3,000 doses will be reserved for citizens with a history of allergy to specific components found in other vaccine preparations. In the last campaign, coverage rates reached 64.9% among those over 65, 9.6% for individuals aged five to 59 with at-risk conditions, and 45% for children between six and 59 months.

The Community of Madrid emphasizes that vaccination is "the most effective measure" to prevent seasonal flu and its potential complications, hospitalizations, and associated deaths. Prevention campaigns for this disease have been conducted uninterruptedly in the region since 1991, progressively expanding the vaccination indication groups based on available evidence.

The Ministry of Health will announce the specific start date of the campaign as autumn approaches.